Multi-Target Docking for Polypharmacology
By Pauling.AI Team
Much of structure-based drug discovery has been built around selectivity: one molecule, one primary target, and the cleanest binding profile medicinal chemistry can produce. That approach has delivered medicines. But it can become limiting when disease biology is spread across connected pathways rather than controlled by one dominant node.
Many cancers, neurodegenerative conditions, and psychiatric or metabolic disorders involve feedback loops, pathway redundancy, and compensatory mechanisms. Block one kinase and a neighboring pathway may take over. In other cases, strong biochemical potency fails to translate into a meaningful disease-model effect because inhibiting the target is not enough. The target may be relevant, but the network still finds a way around it.
Polypharmacology starts from a different objective. The aim is to create a defined activity pattern across several targets. A molecule that modulates proteins in the same pathway, or across parallel pathways, may produce an effect that a selective inhibitor cannot reach. Doing this intentionally is harder than optimizing against one pocket, which is where structure-based methods become useful.
Why docking is useful, and where the simple version breaks down
Docking predicts how a small molecule may fit within a binding pocket and assigns a score intended to reflect the favorability of that pose. To explore whether one compound could bind several proteins, docking it against each target is an obvious first step. Run the ligand against targets A, B, and C, inspect the poses and contacts, and build an initial multi-target profile.
That simplicity is also where multi-target studies become misleading.
Docking scores are not binding free energies. They are approximate outputs from a scoring function, and their absolute values should not be treated as directly comparable across unrelated pockets. A score of -9 against one target and -8 against another does not establish that the compound prefers the first. The pockets differ in size, polarity, flexibility, and scoring behavior. Each target carries its own systematic error. Ranking affinity across proteins from raw docking scores creates a clean-looking result from numbers never calibrated for that purpose.
The more useful question is not “which target does this compound bind best?” It is more specific: does the compound produce a credible binding hypothesis for each target, and does the predicted pose satisfy the structural requirements known for that pocket? Multi-target docking works best when every protein is evaluated independently rather than when the panel is compressed into one leaderboard.
Building a multi-target panel
A multi-target workflow begins with the panel, a biological and medicinal chemistry decision before it becomes a computational one.
The first group contains the intended targets: the proteins whose combined modulation supports the therapeutic hypothesis. A second group contains anti-targets that should be avoided because their engagement may introduce toxicity, poor selectivity, or another liability. A secondary target that contributes to the desired mechanism is not an off-target, while an unintended protein outside the design hypothesis still is.
This distinction matters. A program that optimizes only for the proteins it wants to hit, without tracking those it needs to avoid, risks producing a promiscuous compound and calling it polypharmacology.
Once the panel is selected, every receptor must be prepared carefully and independently. Protonation states, tautomers, cofactors, metals, conserved waters, binding-site boundaries, and representative conformations require target-specific decisions. Flexible pockets may need more than one structure. A shortcut during preparation affects the poses, interaction patterns, and conclusions that follow. Preparation standards should not fall because the panel contains ten receptors.
Reading the results without overclaiming
Once poses are available, the analysis should move beyond the score. What interactions appear in each pocket? Are the known pharmacophoric requirements satisfied? Does the ligand reproduce contacts seen in reference compounds? Is the orientation chemically sensible, or is the scoring function rewarding an implausible geometry?
A pose with a favorable score but without a key interaction is not strong evidence of binding. It is a hypothesis that needs to be questioned. Even within one target, score-based ranking is best treated as an initial filter. Across several targets, interaction-level review matters more because the outputs cannot simply be compared side by side.
The compounds worth advancing produce credible poses across intended targets while showing weak, inconsistent, or absent binding hypotheses at the anti-targets. This does not prove engagement, affinity, or cellular activity. It helps prioritize which molecules to test.
The profile can be built from target-specific criteria such as pose quality, required contacts, similarity to known binding modes, ranking within each receptor, and the absence of convincing interactions in anti-targets. Interaction fingerprints or a target-by-compound heatmap are often more informative than a composite score. The aim is not to identify the strongest score. It is to find a molecule whose overall pattern matches the biology the program is trying to influence.
Selectivity becomes a profile rather than one number. The desired molecule should be active where needed, limited where it should not bind, and balanced enough that one target does not dominate the pharmacology unintentionally.
Where this fits in a computational workflow
Multi-target docking and counter-screening use much of the same machinery, but they ask different questions. Counter-screening looks for evidence that a compound avoids selected liabilities. Multi-target docking looks for a predefined combination of credible binding hypotheses across intended targets while maintaining separation from anti-targets. One searches for cleanliness; the other for a deliberate pattern.
At scale, this changes how early screening is organized. Instead of ranking a library against one receptor, each compound can be profiled across the panel. Prioritization depends on the full pattern: which targets show plausible binding modes, which key contacts are present, and where liabilities appear.
The output is not one ranked list. It is a collection of profiles. That changes the medicinal chemistry discussion from “how well does this compound score against the target?” to “does its predicted target pattern match what the therapeutic hypothesis requires?”
Docking still has clear limits. A plausible pose does not establish potency, target occupancy, or functional direction. It cannot reliably tell whether binding will produce inhibition, activation, agonism, antagonism, or the pathway-level effect the program needs. Those questions require target-specific modeling, experimental assays, and cellular and in vivo confirmation.
What docking can do is narrow the field. It can identify molecules with a credible structural rationale before synthesis and testing resources are committed. For diseases where a single-target strategy has not been sufficient, examining a broader binding profile early can change which compounds move forward.
The one-target model was never a rule of biology. It was a useful simplification that made drug discovery easier to organize. Multi-target docking offers a way to reintroduce some of that complexity deliberately, without pretending that one score can explain the whole system.
.